Compare Sanofi SA (SNY) vs ThredUp Inc (TDUP) Price & Performance

SNY trades at $43.78, up 0.51% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales outlook. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%. Key growth driver Dupixent surpassed €5 billion in quarterly sales, supporting positive sentiment amid pipeline adjustments under new CEO Belen Garijo.

SNY presents a mixed outlook with solid fundamentals and recent earnings beats offset by pipeline setbacks and competitive risks. The stock's valuation metrics, including a P/E of 23.38 and P/S of 1.88, appear reasonable relative to peers. However, investors face risks from biosimilar threats to Dupixent post-2031 and regulatory scrutiny. Analyst consensus leans neutral with 44% buy ratings, suggesting cautious optimism for upside potential driven by execution on new drug launches and cost discipline.

ThredUp (TDUP) trades at $3.17, up 0.96% on the day, but remains under pressure after a significant Q2 2026 earnings miss and lowered full-year revenue guidance. The stock's technical picture is bearish, while fundamentals show improving revenue growth but persistent losses. Recent news highlights an ongoing securities investigation related to the guidance revision, contributing to negative sentiment.

The outlook is cautious. While analyst consensus is technically 'Buy' (57% of ratings), recent operational setbacks and the stock's sharp decline post-earnings suggest significant near-term risk. The primary opportunity lies in the company's high gross margins and active buyer growth, but profitability remains elusive and investor confidence is fragile.